MIM. Yu. Ivanova

M. Yu. Ivanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


M. Yu. Ivanova has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospects of using mesenchymal stromal cells for the treatment of the male urogenital system

    by O. V. Payushina, D. A. Tsomartova, Ye. V. Chereshneva, M. Yu. Ivanova, M. S. Pavlova, S. L. Kuznetsov

    Mesenchymal stromal cells (MSCs) are a promising resource for cell therapy due to multiple differentiation potentials and the ability to exert a complex pro-regenerative effect on injured tissues. The results of numerous studies indicate the possibility of their use in the treatment of the most common diseases of the male urogenital system. In particular, experimental models of toxic, ischemic or traumatic testicular injury, cryptorchidism and fasting-induced testicular insufficiency have shown the beneficial effect of MSC transplantation or injection of their secretory products on the restoration of spermatogenesis and testosterone production. Due to their immunomodulatory properties, MSCs may be useful for the treatment of acute and chronic prostatitis. It is possible that their inherent tropism to tumors can also be used in the treatment of prostate cancer. However, due to the ambiguity of the MSC effect on the tumor process, their use in this field of medicine should be considered with caution. There are also encouraging results of MSC transplantation in erectile dysfunction caused by age-related changes, diabetes mellitus, impaired penile blood supply or innervation, irradiation or Peyronie disease. Experimental data on the therapeutic effects of MSCs obtained in numerous animal studies, and in some cases in clinical trials, can become the basis for the development of new approaches to the treatment of diseases of the main organs of the male urogenital system.

  • Open Access

    Biomarkers of neuroinflammation in the diagnosis of traumatic brain injury and neurodegenerative diseases: a literature review

    by E. A. Kuzmin, Z. V. Shamitko, G. A. Piavchenko, A. A. Venediktov, M. Yu. Ivanova, S. L. Kuznetsov

    Inflammatory processes accompanied by damage to the cell bodies of neurons are combined into the group of neuroinflammation. At the molecular, cellular and tissue levels, neuroinflammation serves as a sanogenetic response to a variety of injuries, including post-traumatic conditions and neurodegeneration. However, inflammatory changes in long-lived cells such as neurons inevitably trigger a range of adverse effects. As a result, prognosis often depends on the severity of neuroinflammation. In this work, we review the spectrum of biomarkers involved in two key mechanisms of neuroinflammation: immune-mediated and mechanical injury, that have a potential clinical application: cytokines, neurospecific proteins and their proteolysis products, markers of oxidative stress, matrix metalloproteinases and endocrine parameters. Over the past decades, a significant pool of data on neuroinflammation biomarkers has been accumulated and continues to grow, but no consensus has been reached on the actual gradation of their clinical significance. Applied branches of medicine require further systematization of information on biomarkers of neuroinflammation for effective prognostic decisions.


  • Open Access

    Ways to increase the regenerative potential of mesenchymal stromal cells

    by O. V. Payushina, D. A. Tsomartova, E. V. Chereshneva, M. Yu. Ivanova, S. G. Mukhamedova, M. S. Pavlova, S. L. Kuznetsov

    The ability of mesenchymal stromal cells (MSCs) to migrate into tissue defects and stimulate regeneration makes them a valuable resource for cell therapy. However, in many cases, in vitro cultivation and the influence of the pathological microenvironment in the patient’s body reduce the viability and therapeutic efficacy of MSCs, so their regenerative potential needs to be strengthened. Preconditioning with hormones, cytokines, various chemical or physical factors, cultivation in a three-dimensional environment or at a reduced oxygen content improves the ability of MSCs to colonize damaged tissue, survive in it, and produce regulatory molecules for regeneration. The same goals can be achieved by genetic modification of MSCs. In addition, with the help of transfected MSCs, it is possible to deliver genes necessary for the treatment of hereditary or oncological diseases into the tissue. Finally, an alternative to avoid a decrease in the therapeutic potential of subsequently transplanted MSCs during cultivation can be stimulation of the migration of endogenous patient cells from tissue niches through the systemic circulation to the area of damage. The development of these approaches opens the way to increasing the efficiency of using MSCs in regenerative medicine.

  • New perspectives on treatment of gastrointestinal diseases: therapeutic potential of mesenchymal stromal cells

    by Olga Payushina, Dibakhan Tsomartova, Yelizaveta Chereshneva, Marina Ivanova, Nataliya Pashina, Elina Tsomartova, Sergey Kuznetsov

    Mesenchymal stromal cells (MSCs) are a promising resource for cell therapy of different organs and systems, including the gastrointestinal tract (GIT). Therapeutic effect of MSC transplantation in GIT diseases may be partly due to their differentiation into various cellular components of the digestive tube. However, more significant is regulatory influence of MSCs on survival, proliferation, and differentiation of the gastric and intestinal epithelial cells, as well as their immunomodulatory, pro-angiogenic and antifibrotic effects. Data from experiments on animals and clinical trials indicate prospect of using MSCs in various diseases affecting any parts of GIT. However, effective and safe clinical use of MSCs requires an in-depth study of the mechanisms of their therapeutic effect, the development of optimal methods of administration, and risk assessment of adverse effects. This review analyzes MSC participation in regeneration of GIT and systematizes data on the potential of using MSCs in the treatment of gastroenterological diseases.

  • Open Access

    Role of mesenchymal stromal cells and their secretory products in kidney regeneration

    by O. V. Payushina, D. A. Tsomartova, E. V. Chereshneva, M. Yu. Ivanova, T. A. Lomanovskaya, S. L. Kuznetsov

    Kidney diseases are an important medical problem. Kidney injuries are accompanied by oxidative stress, cell death, capillary destruction, inflammation and fibrosis. Mesenchymal stromal cells (MSCs) have a complex effect on the regeneration by producing various regulatory molecules, including those inside extracellular vesicles, and therefore are considered as a promising therapeutic resource for cell therapy of kidney diseases. Their renoprotective effect has been shown in different experimental models, but the results of the clinical trials are ambiguous. Clinical use of MSCs is complicated by their low survival rate in the injured kidney, potential immunogenicity, tumorogenicity and fibrogenicity. Cell-free therapy with the secretory products of MSCs such as conditioned environments or extracellular vesicles is a promising direction for using their regenerative potential. However, introduction of MSCs and their secretory products into medical practice requires further research into the mechanisms of their proregenerative action, improvement of cultivation protocols, and more clinical trials.


  • Open Access

    Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links

    by Oksana Sulaieva, Oleksii Selezniov, Dmytro Shapochka, Nataliia Belemets, Oleksandr Nechay, Yelizaveta Chereshneva, Dibakhan Tsomartova, Marina Ivanova


  • Open Access

    The role of Epstein-Barr viral infection and hepatitis B and C in liver pathology

    by T. V. Solomay, T. A. Semenenko, M. Yu. Ivanova

    A review of scientific literature data on clinical and epidemiological characterization of viral hepatitis B, C and Epstein-Barr viral infection is presented. Scopus, Web of Science, MedLine, The Cochrane Library, PubMed, CyberLeninka, RSCI databases were used to find the necessary literature. It was shown that Epstein-Barr virus along with hepatitis B and C viruses plays a significant role in the development of virus-mediated autoimmune liver diseases, as well as other organs (intestine, heart, kidneys, thyroid gland, etc.). The similarity of these nosologies is also evident in the nature of the course of the disease: the presence of a primary infection in a manifest or latent form, with possible subsequent chronization of the process and its periodic reactivation. Wide distribution of pathogens in the human population determines the possibility of mixed infections with Epstein-Barr virus and hepatitis B and C viruses, however, this problem has not been adequately described in the scientific literature. The review suggests that the role of Epstein-Barr virus in the development of liver diseases and extrahepatic pathology should not be ignored, and the combination of this pathogen with hepatitis B and C viruses required further in-depth studies.


  • Open Access

    Calf demand provision by mammary gland secretion during the first decade of post-natal development

    by Sergii Shapovalov, Sergei Mikhaylov, Skryl Andrey, Yelizaveta Chereshneva, Dibahan Tsomartova, Marina Ivanova, Elina Tsomartova, Diana Shapovalova, Mariia Pavlova


  • Impact of Na+/I– symporter to non-oncologic pathology of the thyroid

    by Dibahan Tsomartova, Elizaveta Chereshneva, Marina Ivanova, Sergey Pashin, Sergey Kuznetsov